![Jonathan R. Savidge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan R. Savidge
Algemeen Directeur bij Syndesi Therapeutics SA
Actieve functies van Jonathan R. Savidge
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Algemeen Directeur | - | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Voorzitter | 26-04-2023 | - |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Algemeen Directeur | - | - |
Loopbaan van Jonathan R. Savidge
Eerdere bekende functies van Jonathan R. Savidge
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 01-06-2013 | - |
UCL Business Ltd.
![]() UCL Business Ltd. Miscellaneous Commercial ServicesCommercial Services UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01-01-2002 | - |
Opleiding van Jonathan R. Savidge
University of Oxford | Undergraduate Degree |
The University of Manchester | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 6 |
Israël | 2 |
België | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Chief Executive Officer | 2 |
Undergraduate Degree | 1 |
Sectoraal
Commercial Services | 4 |
Consumer Services | 3 |
Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BICYCLE THERAPEUTICS PLC | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
UCL Business Ltd.
![]() UCL Business Ltd. Miscellaneous Commercial ServicesCommercial Services UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Commercial Services |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Health Technology |
- Beurs
- Insiders
- Jonathan R. Savidge
- Ervaring